Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Buprenorphine/naloxone transmucosal - BioDelivery Sciences International

Next Previous
Search
Drug Profile

Buprenorphine/naloxone transmucosal - BioDelivery Sciences International

Alternative Names: B-BNX; BEMA® Buprenorphine NX; BEMA® Buprenorphine/Naloxone; BNX; BUNAVAIL; Buprenorphine and naloxone buccal film; Buprenorphine/Naloxone buccal soluble film; Naloxone/buprenorphine - BioDelivery Sciences International; Naloxone/buprenorphine transmucosal - BioDelivery Sciences International

Latest Information Update: 10 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioDelivery Sciences International
  • Class Antidotes; Benzofurans; Cyclopropanes; Drug withdrawal therapies; Isoquinolines; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists; Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Opioid-related disorders

Most Recent Events

  • 03 Mar 2023 Aquestive Therapeutics reached an agreement with BioDelivery Sciences for the commercialisation of buprenorphine buccal and buprenorphine/naloxone transmucosal drug film products in the US
  • 22 Mar 2022 BioDelivery Sciences International has been acquired by Collegium Pharmaceutical
  • 12 Oct 2017 BioDelivery Sciences settles litigation against Teva over ANDA submission in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top